Saturday , 2 March 2024
Home Health IMFINZI® (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional foll
Health

IMFINZI® (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional foll

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

 

Continue reading your article with a FrontPage News Subscription

Already a Subscriber? Sign In  

OR
VIEW SUBSCRIPTION OPTIONS
Support independent journalism by subscribing